Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31;27(5):875-880.
doi: 10.5603/RPOR.a2022.0104. eCollection 2022.

Follow-up after breast cancer treatment

Joanna Załuska-Kusz  1 , Maria Litwiniuk  1   2
Affiliations

Follow-up after breast cancer treatment

Joanna Załuska-Kusz et al. Rep Pract Oncol Radiother. .

Abstract

Background: Breast cancer (BC) is the most common malignancy in women. Due to improved detectability and modern methods of treatment, the number of breast cancer survivors is estimated at 6 million women globally and is still increasing. The follow-up (FU) visits carried out at the Greater Poland Cancer Centre were assessed for compliance with Polish Society of Clinical Oncology (PTOK) and European Society for Medical Oncology (ESMO) guidelines.

Materials and methods: The database covered 484 women who were treated for breast cancer in the Greater Poland Cancer Centre in 2013. Of these, 233 attended FU visits for 5 years after completion of radical treatment and had no cancer relapse. The number of FU visits and the number and type of additional tests performed were analyzed.

Results: The median number of FU visits over 5 years was 14, which is in line with the guidelines. 51.6% women had a mandatory annual mammography. A significant number of women had additional tests that are not recommended in the guidelines.

Conclusions: There is a need to educate both physicians and patients on the principles of FU check-ups.

Keywords: breast cancer; follow-up; scientific societies guidelines.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest None declared.

References

    1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Jassem J, Krzakowski M, Bobek-Bilewicz B, et al. Breast cancer. Oncol Clin Pract. 2020;16(5):207–260.
    1. Senkus E, Kyriakides S, Ohno S, et al. ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30. doi: 10.1093/annonc/mdv298. - DOI - PubMed
    1. Geurts SME, de Vegt F, Siesling S, et al. Pattern of follow-up care and early relapse detection in breast cancer patients. Breast Cancer Res Treat. 2012;136(3):859–868. doi: 10.1007/s10549-012-2297-9. - DOI - PubMed
    1. Hayes DF. Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med. 2007;356(24):2505–2513. doi: 10.1056/NEJMcp067260. - DOI - PubMed

LinkOut - more resources